SL4903 CAR-T therapy for returning multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell treatment for multiple myeloma that has come back or not responded to prior therapies. It aims to see if SL4903 can safely and effectively target cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your multiple myeloma has returned or not responded after at least one prior treatment, including a proteasome inhibitor, an immunomodulatory drug, and a CD38-targeting drug.
- You have measurable disease, such as a certain level of M-protein in blood or urine, or a soft tissue tumor at least 2 cm wide.
- You are in generally good health, able to care for yourself (ECOG 0-2), and have adequate organ function, including heart, kidney, and liver.
- You have not had a prior CAR-T therapy targeting BCMA or GPRC5D, and you do not have active infections, certain brain conditions, or other uncontrolled cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins on myeloma cells: GPRC5D and CD19. It is for people whose myeloma has come back or stopped responding to at least 3 prior treatments. The goal is to see if this treatment is safe and helps control the disease.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
Hear when a new Relapsed and Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.